Research programme: HIV protease inhibitors - Medivir/Tibotec

Drug Profile

Research programme: HIV protease inhibitors - Medivir/Tibotec

Alternative Names: HIV-PI therapeutics - Medivir/Tibotec Pharmaceuticals/J&J

Latest Information Update: 17 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medivir AB
  • Developer Janssen R&D Ireland; Medivir AB
  • Class
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 17 Mar 2011 This research programme is ongoing in Sweden
  • 07 Jan 2008 Medivir and Tibotec extend their collaboration for a further year
  • 05 Jun 2007 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top